Mizuho Securities analyst maintained a Buy rating on Assembly Biosciences ( – ) today and set a price target of $3.00. The company’s shares opened today at $1.53.

Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to , Syed has an average return of -10.9% and a 43.14% success rate on recommended stocks.

Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.

The company has a one-year high of $2.42 and a one-year low of $0.82. Currently, Assembly Biosciences has an average volume of 321.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which are most likely to make moves following their insider activities.

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Read More on ASMB: